Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Simulation in In Vitro Bioequivalence for Particle Sizes
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.